Wells Fargo has designated Annexon, Inc. (ANNX) as its top pick in the biotechnology sector, maintaining an Overweight rating and a $27.00 price target. The firm highlights a compelling setup ahead of a critical Q4 2026 data readout for its ARCHER II trial in generalized myasthenia gravis (GA) .
Key points:
- Wells Fargo assigns a 55% probability of success for a positive Month-15 outcome in the ARCHER II trial, projecting a potential 3-4x stock re-rating .
- The company's tanruprubart Biologics License Application is on track for Q4 2026 submission .
- Annexon ended Q3 2026 with $213M in cash, with management reiterating financial runway into 2028 .
Wells Fargo Names Top Pick in Biotechnology Sector
STREETINSIDER.COMNov 11, 5:02 PM UTC
0